SEC Filing Summary: AspenBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio, Inc. on August 30, 2004. The report details the entry into a material definitive agreement regarding executive compensation and corporate governance. Note: The request metadata referenced "Riot Platforms, Inc."; however, the source text explicitly identifies the registrant as AspenBio, Inc.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt levels. The only specific financial figures disclosed relate to the new executive agreement:
- Executive Compensation: Annual salary of $100,000 for the President.
- Share Contribution: The President contributed 1,896,757 common shares back to the company for no consideration.
- Debt Reduction: An agreed-upon reduction in a note owed to the President was executed as part of the agreement.
Material Changes
The primary material change is the execution of a new employment agreement with President Roger Hurst, effective September 1, 2004. Key changes include:
- Formalization of a one-year employment term with automatic renewal.
- Termination of a previous voting agreement.
- Restrictions on the company's right to cancel the agreement while indebtedness guaranteed by Mr. Hurst remains outstanding.
- Post-contribution ownership of 2,000,000 shares by Mr. Hurst.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or general management commentary regarding business strategy. The document focuses strictly on the contractual terms of the employment agreement, including standard provisions for non-competition, confidentiality, indemnification, and termination.
Investor Verification Checklist
- Verify the exact amount of debt reduction achieved in the note owed to Roger Hurst, as the filing states a reduction was made but does not quantify the dollar amount.
- Confirm the current status of the indebtedness guaranteed by Mr. Hurst, as this dictates the company's ability to cancel the employment agreement.
- Review the impact of the 1,896,757 share contribution on the company's total outstanding share count and capitalization.
- Check for any subsequent filings regarding the financial health of AspenBio, Inc., as this 8-K does not provide a balance sheet or income statement.